社区医院大骨科术后利伐沙班与标准抗凝治疗不良事件回顾性评价
该回顾性研究纳入2011年10月至2015年2月间3246例大骨科术后接受利伐沙班、调整剂量华法林或华法林联合依诺肝素预防静脉血栓栓塞的患者,比较术后即刻出血与VTE事件发生率。总体出血和VTE事件罕见,多变量模型显示华法林组及华法林联合依诺肝素组出血发生率显著低于利伐沙班组。
要点
- 大骨科术后利伐沙班组出血发生率为1.2%,华法林组及华法林联合依诺肝素组均为0.4%。
- 多变量模型显示华法林组出血发生率显著低于利伐沙班组(IRR=0.218,p=0.0120)。
- 华法林联合依诺肝素组出血发生率亦显著低于利伐沙班组(IRR=0.242,p=0.021)。
核心结论
- 大骨科术后即刻使用利伐沙班相比华法林或华法林联合依诺肝素,观察到小幅但显著的出血风险增加。
研究设计与样本
- 回顾性研究纳入2011年10月1日至2015年2月28日期间接受大骨科手术后预防VTE、年龄大于18岁的患者3246例。
主要发现
- 出血事件发生率利伐沙班组为1.2%,华法林组和华法林联合依诺肝素组均为0.4%(p=0.088)。
- VTE事件发生率华法林联合依诺肝素组为0.2%,利伐沙班组为0.6%(p=0.230)。
- 共发生2例大出血和18例小出血(包括出血性伤口并发症),2例深静脉血栓和10例肺栓塞。
关键数值与推荐
- 多变量模型中,华法林组相比利伐沙班组出血发生率IRR=0.218(p=0.0120)。
- 华法林联合依诺肝素组相比利伐沙班组出血发生率IRR=0.242(p=0.021)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVES: To evaluate the occurrence of bleeding and venous thromboembolic (VTE) events in patients receiving rivaroxaban, warfarin, or warfarin with the addition of enoxaparin during the immediate postoperative period following major orthopedic surgery. METHODS: Patients older than 18 years who received at least one dose of rivaroxaban the morning following surgery, adjusted dose warfarin, or adjusted dose warfarin with the addition of enoxaparin for VTE prophylaxis after major orthopedic surgery between October 1, 2011, and February 28, 2015, were included. Data collected from the electronic health record included patient demographics, renal function, inpatient aspirin, P2Y12 inhibitor and/or nonsteroidal antiinflammatory drug (NSAID) use, type of surgery, postoperative analgesia, and presence of VTE risk factors. Adjusted incidence rate ratio for bleeding or VTE events was estimated using modified Poisson regression with robust standard errors. Covariates included in a multivariable model were age, sex, aspirin use, P2Y12 inhibitor use, NSAID use, obesity, VTE risk factors, and creatinine clearance. RESULTS: There were 3246 patients who met study inclusion criteria. Overall, incidences of bleeding and VTE events were rare. Bleeding event incidence ranged from 0.4% in the warfarin and warfarin with the addition of enoxaparin groups to 1.2% in the rivaroxaban group (p=0.088). There were two major bleeding events and 18 minor bleeding events (including hemorrhagic wound complications). VTE event incidence ranged from 0.2% in the warfarin with the addition of enoxaparin group to 0.6% in the rivaroxaban group (p=0.230). Two deep vein thromboses and 10 pulmonary emboli occurred. With use of the multivariable model, the warfarin and warfarin with the addition of enoxaparin groups had significantly lower incidence rates of bleeding compared with rivaroxaban (incidence rate ratio [IRR] = 0.218, p=0.0120, and IRR = 0.242, p=0.021, respectively). PRINCIPAL CONCLUSIONS: We observed a small, yet significant, increase in rivaroxaban-related bleeding in the immediate postoperative period relative to warfarin or warfarin with the addition of enoxaparin for the prevention of VTE after major orthopedic surgery.
引用
- Cieri NE, Kusmierski K, Lackie C, et al. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital. Pharmacotherapy. 2017. PMID: 28028830. doi:10.1002/phar.1888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。